Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.
Location: United States, California, Menlo Park
Employees: 11-50
Total raised: $289.5M
Founded date: 2018
Investors 6
| Date | Name | Website |
| 06.07.2021 | Omega Fund... | omegafunds... |
| - | RA Capital... | racap.com |
| - | The Column... | thecolumng... |
| - | TCG Crosso... | tcgcrossov... |
| 17.09.2020 | Canaan Par... | canaan.com |
| - | Bain Capit... | baincapita... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 06.01.2023 | Series C | $100M | - |
| 10.06.2021 | Series B | $107.5M | - |
| 17.09.2020 | Series A | $82M | - |
Mentions in press and media 8
| Date | Title | Description |
| 06.01.2023 | Synthekine Secures $100M Series C Financing | MENLO PARK, CA, Synthekine Inc., an engineered cytokine therapeutics company, announced the closing of a $100 million Series C financing. >> Click here for more funding data on Synthekine >> To export Synthekine funding data... |
| 25.11.2021 | TCG Announces the Addition of TCG iPartners | TCG’s iPartners represents a new ideation advisory group comprised of leading academic investigators and biotech entrepreneurs. Working closely with TCG’s Swanson Fellows and our core investment team, this group is dedicated to crafting inn... |
| 11.06.2021 | In DiDi IPO, a one-time rival Uber stands to gain | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. A few years ago, local ride-hailing upstarts in countries including Southeast Asia and China defe... |
| 10.06.2021 | Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform | Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has closed an oversubscribed $107.5 million Series B financing. The round was co-led by Deerfield Management and Janus Henderson Investors, with participa... |
| 10.06.2021 | Synthekine Announces $107.5 Million Oversubscribed Series B Financing | - |
| 17.09.2020 | Synthekine Scoops Up $82M Series A Round | MENLO PARK, CA, Synthekine, an engineered cytokine therapeutics company, today announced the closing of an $82 million Series A financing. >> Click here for more funding data on Synthekine >> To export Synthekine funding dat... |
| - | Synthekine | “Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory... |
| - | The Column Group Raises a $725 Million Fourth Fund | The Column Group (TCG), a biotech venture capital firm focused on building innovative drug discovery companies, announced the closing of The Column Group IV (TCG IV) and its related investment vehicles totaling $725 million. With TCG IV, th... |